News | September 22, 2010

Study Indicates that New Stent Reduces Risk of Malapposition


September 22, 2010 – Trial data indicate that a new stent may be a safer solution to treat heart attack patients. The Apposition II study found that the Stentys self-apposing stent helps reduce the risk of malapposition in patients who have suffered an acute myocardial infarction (AMI).

The self-apposing stent fits snugly into the contour of a blood vessel. Once implanted, it behaves like a spring, changing its shape and diameter to adapt to the anatomic changes of the coronary arteries during the post-AMI phase.

The trial showed that, three days after the heart attack, 28 percent of patients treated with conventional stents displayed significant malapposition, meaning that the stent is not in contact with the artery wall. This puts patients at significant risk of potential fatal complications such as an implant blockage (in-stent thrombosis). In contrast, none of the patients treated with the Stentys stent had malapposition.

"We are very excited that the primary endpoint of the Apposition II study was reached successfully. The Stentys stents were all perfectly apposed whereas gross malapposition was observed in more than one in four patients treated with conventional stents. This is very important because malapposition is one of the key contributing factors causing stent thrombosis," said principal investigator Stefan Verheye, M.D., Ph.D., Department of Cardiology, Middelheim Hospital, Antwerp, Belgium.

Acute myocardial infarction (AMI) affects 100,000 people each year in France and an additional 900,000 people in the United States.

For more information please visit: www.stentys.com


Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now